UNION CITY, Calif., April 15 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. today announced that it will release financial results for the first quarter ended March 31, 2010 on Thursday, April 29, 2010 after the market close. The Company will host a conference call and webcast on Thursday, April 29, 2010 at 4:30 p.m. Eastern /1:30 p.m. Pacific to discuss the Company’s first quarter and current corporate developments. The dial-in number for the conference call is 877-941-9205 for domestic participants and 480-629-9039 for international participants.
About Questcor
Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets H.P. Acthar(R) Gel (repository corticotropin injection). H.P. Acthar Gel (“Acthar”) is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis (“MS”) and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms (“IS”), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The Company also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.
CONTACT: CONTACT: Don Bailey of Questcor Pharmaceuticals, Inc.,
+1-510-400-0776, dbailey@Questcor.com; or Investors, Doug Sherk, or Barbara
Domingo, +1-415-896-6820, or Media Christopher Gale, +1-646-201-5431, all
of EVC Group, Inc., for Questcor Pharmaceuticals, Inc.
Web site: http://www.questcor.com/
